This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Replacement of growth hormone (GH) in HIV infected adults has been proven to increase lean tissue mass and clinical stats. Previous studies have been conducted using daily subcutaneous injections for up to six months. The purpose of this study is to compare the metabolic effects of GH depot to daily GH, and to study short-term and long-term (12 months) metabolic effects of GH in the HIV-infected adult males. (Males only will be included in this small pilot study to provide as much uniformity in the subject population as possible. After pilot data is analyzed, a larger study to include women is planned for a grant submission.) The study population will include 10 patients with and 10 patients without lipoatrophy evenly distributed on either subcutaneous daily Nutropin AQ or Nutropin Depot. The major endpoint will be change in lean tissue and body composition as measured by DXA scan. The other study endpoints include: hepatic glucose production, gluconeogenesis, protein turnover, bone mineral turnover and TNF-alpha levels. This study will provide new long-term information on the metabolic effects of GH in HIV-infected adults.
Showing the most recent 10 out of 693 publications
